Complete title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
| Research Study Number | S1609 |
| Principal Investigator | Heidi Gray, MD |
| Phase | II |
Other eligibility criteria may apply.
| Research Study Number | S1609 |
| Contact | Seattle Cancer Care Alliance Intake Office |
| Telephone | 800-804-8824 / 206-606-1024 |
Keywords: Head and Neck Cancer; Nasopharyngeal Cancer; Ovarian Cancer; Pituitary Tumor; Salivary Gland Cancer; Solid Tumors; Stomach Cancer; Testicular Cancer; Thyroid Cancer; Neoplasms, Germ Cell and Embryonal; Neuroendocrine Tumor; Neoplasms; Neoplasms, Glandular and Epithelial; Otorhinolaryngologic Neoplasms; Endocrine Gland Neoplasms; Neoplasms, Squamous Cell; Pharyngeal Neoplasms; Carcinoid Tumor; Immunotherapy; Nerve Sheath Neoplasms; Trophoblastic Neoplasms; Neoplasms, Second Primary; Carotid Body Tumor; Sex Cord-Gonadal Stromal Tumors; Trophoblastic Tumor, Placental Site; Parathyroid Neoplasms; Mixed Tumor, Mullerian; Odontogenic Tumors; Paranasal Sinus Neoplasms
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.